Approval · Notice of Compliance 17238 · 2015
VECTIBIX: Notice of Compliance 17238
Issued August 31, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17238
- Date
- August 31, 2015
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional indication: vectibix is indicated for the treatment of previously untreated patients with non-mutated (wild-type) ras metastatic colorectal carcinoma (mcrc) in combination with folfox
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VECTIBIX | Not yet assigned | — |
Medicinal ingredients
- PANITUMUMAB 20 MG per ML